Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer
- Determine the response rate and duration of response in patients with stage IIIB or IV
non-small cell lung cancer treated with carboplatin, irinotecan, and thalidomide.
- Determine the progression-free and overall survival of patients treated with this
- Evaluate the toxicity profile of this regimen in these patients.
OUTLINE: Patients receive carboplatin IV over 30 minutes on day 1 and irinotecan IV over 90
minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression
or unacceptable toxicity. Patients with stable or responsive disease receive up to 6 courses
of therapy. Patients also receive oral thalidomide once daily beginning on day 1 and
continuing until disease progression.
Patients are followed every 3 months until disease progression and then every 6 months
PROJECTED ACCRUAL: A total of 39-70 patients will be accrued for this study within 14
Primary Purpose: Treatment
Antonius A. Miller, MD
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
|CCOP - Upstate Carolina||Spartanburg, South Carolina 29303|
|Comprehensive Cancer Center at Wake Forest University||Winston-Salem, North Carolina 27157-1082|
|CCOP - Central Illinois||Springfield, Illinois 62526|
|CCOP - Greenville||Greenville, South Carolina 29615|
|Southeastern Medical Oncology Center||Goldsboro, North Carolina 27534|